

Endpoint dilution using an antibody to the adenoviral hexon protein may be used to quantitate virus production or infection efficiency of target cells (Armentano et al. (1995) Hum. Gene Ther. 6:1343-53.

In addition to containing the DNA sequences encoding one or more transgenes, the chimeric adenoviral vectors of the invention may contain any expression control sequences such as a promoter or enhancer, a polyadenylation element, and any other regulatory elements that may be used to modulate or increase expression, all of which are operably linked in order to allow expression of the transgene. The use of any expression control sequences, or regulatory elements, which facilitate expression of the transgene is within the scope of the invention. Such sequences or elements may be capable of generating tissue-specific expression or be susceptible to induction by exogenous agents or stimuli.

#### **Construction of Retroviral Vectors**

The antigen presenting cells described herein can also be genetically modified with retroviral vectors produced recombinantly by procedures already taught in the art. For example, WO 94/29438 describes the construction of retroviral packaging plasmids and packaging cell lines. As is apparent to the skilled artisan, the retroviral vectors useful in the methods of this invention are capable of infecting the cells described herein. The techniques used to construct vectors, and transfect and infect cells are widely practiced in the art. Examples of retroviral vectors are those derived from murine, avian or primate retroviruses. Retroviral vectors based on the Moloney murine leukemia virus (MoMLV) are the most commonly used because of the availability of retroviral variants that efficiently infect human cells. Other suitable vectors include those based on the Gibbon Ape Leukemia Virus (GALV) or HIV.

The range of host cells that may be infected by a retrovirus or retroviral vector is determined by the viral envelope protein. The recombinant virus can be used to infect virtually any other cell type recognized by the env protein provided by the packaging cell, resulting in the integration of the viral genome in the

transduced cell and the stable production of the foreign gene product. In general, murine ecotropic env of MoMLV allows infection of rodent cells, whereas amphotropic env allows infection of rodent, avian and some primate cells, including human cells. Amphotropic packaging cell lines for use with MoMLV systems are known in the art and commercially available and include, but are not limited to, PA12 and PA317. Miller et al. (1985) Mol. Cell. Biol. 5:431-437; Miller et al. (1986) Mol. Cell. Biol. 6:2895-2902; and Danos et al. (1988) Proc. Natl. Acad. Sci. USA 85:6460-6464. Xenotropic vector systems exist which also allow infection of human cells.

The host range of retroviral vectors has been altered by substituting the env protein of the base virus with that of a second virus. The resulting, "pseudotyped", virus has the host range of the virus donating the envelope protein and expressed by the packaging cell line. Recently, the G-glycoprotein from vesicular stomatitis virus (VSV-G) has been substituted for the MoMLV env protein. Burns et al. (1993) Proc. Natl. Acad. Sci USA 90:8033-8037; and PCT patent application WO 92/14829. Since infection is not dependent on a specific receptor, VSV-G pseudotyped vectors have a broad host range.

Usually, the vectors will contain at least two heterologous genes or gene sequences: (i) the therapeutic gene to be transferred; and (ii) a marker gene that enables tracking of infected cells.

The viral vector can be modified to incorporate chimeric envelope proteins or nonviral membrane proteins into retroviral particles to improve particle stability and expand the host range or to permit cell type-specific targeting during infection. The production of retroviral vectors that have altered host range is taught, for example, in WO 92/14829 and WO 93/14188. Retroviral vectors that can target specific cell types *in vivo* are also taught, for example, in Kasahara et al. (1994) Science 266:1373-1376. Kasahara et al. describe the construction of a Moloney leukemia virus (MoMLV) having a chimeric envelope protein consisting of human erythropoietin (EPO) fused with the viral envelope protein. This hybrid virus shows tissue tropism for human red blood progenitor cells that bear the

receptor for EPO, and is therefore useful in gene therapy of sickle cell anemia and thalassemia. Retroviral vectors capable of specifically targeting infection of cells are preferred for *in vivo* gene therapy.

5 The vector construct is introduced into a packaging cell line which will generate infectious virions. Packaging cell lines capable of generating high titers of replication-defective recombinant viruses are known in the art, see for example, WO 94/29438. Viral particles are harvested from the cell supernatant and purified for *in vivo* infection using methods known in the art such as by filtration of supernatants 48 hours post transfection. The viral titer is determined by infection  
10 of a constant number of appropriate cells (depending on the retrovirus) with titrations of viral supernatants. The transduction efficiency can be assayed 48 hours later by a variety of methods, including Southern blotting.

After viral transduction, the presence of the viral vector in the transduced cells or their progeny can be verified such as by PCR. PCR can be performed to  
15 detect the marker gene or other virally transduced sequences. Generally, periodic blood samples are taken and PCR conveniently performed using e.g. NeoR probes if the NeoR gene is used as marker. The presence of virally transduced sequences in bone marrow cells or mature hematopoietic cells is evidence of successful reconstitution by the transduced cells. PCR techniques and reagents are well  
20 known in the art. See, generally, PCR PROTOCOLS, A GUIDE TO METHODS AND APPLICATIONS. Innis, Gelfand, Sninsky & White, eds. (Academic Press, Inc., San Diego, 1990) and commercially available (Perkin-Elmer).

*In vitro/ex vivo*, exposure of human DCs to adenovirus (Ad) vector at a multiplicity of infection (MOI) of 500 for 16-24 h in a minimal volume of serum-free medium reliably gives rise to transgene expression in 90-100% of DCs. The  
25 efficiency of transduction of DCs or other APCs can be assessed by immunofluorescence using fluorescent antibodies specific for the tumor antigen being expressed (Kim et al., 1997). Alternatively, the antibodies can be conjugated to an enzyme (e.g. HRP) giving rise to a colored product upon reaction

with the substrate. The actual amount of antigen being expressed by the APCs can be evaluated by ELISA.

Transduced APCs can subsequently be administered to the host via an intravenous, subcutaneous, intranasal, intramuscular or intraperitoneal route of delivery.

*In vivo* transduction of DCs, or other APCs, can potentially be accomplished by administration of Ad (or other viral vectors) via different routes including intravenous, intramuscular, intranasal, intraperitoneal or cutaneous delivery. The preferred method is cutaneous delivery of Ad vector at multiple sites using a total dose of approximately  $1 \times 10^{10}$ - $1 \times 10^{12}$  i.u. Levels of *in vivo* transduction can be roughly assessed by co-staining with antibodies directed against APC marker(s) and the TAA being expressed. The staining procedure can be carried out on biopsy samples from the site of administration or on cells from draining lymph nodes or other organs where APCs (in particular DCs) may have migrated. The amount of TAA being expressed at the site of injection or in other organs where transduced APCs may have migrated can be evaluated by ELISA on tissue homogenates.

Although viral gene delivery is more efficient, DCs can also be transduced *in vitro/ex vivo* by non-viral gene delivery methods such as electroporation, calcium phosphate precipitation or cationic lipid/plasmid DNA complexes. Transduced APCs can subsequently be administered to the host via an intravenous, subcutaneous, intranasal, intramuscular or intraperitoneal route of delivery.

*In vivo* transduction of DCs, or other APCs, can potentially be accomplished by administration of cationic lipid/plasmid DNA complexes delivered via the intravenous, intramuscular, intranasal, intraperitoneal or cutaneous route of administration. Gene gun delivery or injection of naked plasmid DNA into the skin also leads to transduction of DCs. Intramuscular delivery of plasmid DNA may also be used for immunization.

The transduction efficiency and levels of transgene expression can be assessed as described above for viral vectors.

### Expansion of Immune Effector Cells

5 The present invention makes use of these APCs to stimulate production of an enriched population of antigen-specific immune effector cells. The antigen-specific immune effector cells are expanded at the expense of the APCs, which die in the culture. The process by which naïve immune effector cells become educated by other cells is described essentially in Coulic (1997) *Mol. Med.*  
10 *Today* 3:261-268.

In a preferred embodiment, the antigen-specific immune effector cells are CTLs. In one aspect, the cytotoxic T cells are polyclonal T cells isolated from a site of cytotoxic T cell infiltration from a subject. Alternatively, such cells may be isolated from a site of cytotoxic T cell infiltration from two or more subjects or  
15 human patients, in which the subjects share an MHC halotype. In another embodiment, the CTLs may be two or more cytotoxic T cell lines. In yet another embodiment, the CTLs may be any combination of the foregoing.

In a further aspect of the invention, the site of cytotoxic T cell infiltration is a tumor. The tumors from which cells or cell lines are obtained can be the same  
20 type of tumor in different individuals with a shared MHC halotype or different types of tumors from different subjects who share an MHC haplotype.

The APCs prepared as described above are mixed with naïve immune effector cells. Preferably, the cells may be cultured in the presence of a cytokine, for example IL2. Because dendritic cells secrete potent immunostimulatory  
25 cytokines, such as IL2, it may not be necessary to add supplemental cytokines during the first and successive rounds of expansion. In any event, the culture conditions are such that the antigen-specific immune effector cells expand (*i.e.* proliferate) at a much higher rate than the APCs. Multiple infusions of APCs and optional cytokines can be performed to further expand the population of antigen-  
30 specific cells.

In one embodiment, the immune effector cells are T cells and are specific for tumor-specific antigens which are presented by the APCs.

### Compositions

5 This invention also provides compositions containing any of the above-mentioned proteins, muteins, polypeptides, nucleic acid molecules, vectors, cells, antibodies and fragments thereof, and an acceptable solid or liquid carrier. When the compositions are used pharmaceutically, they are combined with a "pharmaceutically acceptable carrier" for diagnostic and therapeutic use. These  
10 compositions also can be used for the preparation of medicaments for the diagnosis and treatment of diseases such as cancer.

### Tumor Protection in Animal Models

15 Applicants are the first to establish that, based on the animal models described below, prevaccination with the compositions of this invention will prevent or delay onset of disease.

The murine B16 melanoma model was used. In this model, C57BL/6 mice were immunized with bone marrow-derived DCs transduced with an Ad vector encoding either human gp100 (Ad/hugp100) or mouse gp100 (Ad/mgp100). Mice  
20 immunized against heterologous human gp100 developed a protective immune response and were resistant to a lethal subcutaneous challenge of B16 melanoma cells (syngeneic tumor cell line that expresses gp100). In contrast, mice immunized with homologous mouse gp100 failed to mount a protective immune  
25 injection. This finding illustrates the difficulty in breaking tolerance against a self antigen (mouse gp100). The corresponding heterologous antigen from a different species (human gp100), however, is likely to contain several Class I and Class II-associated epitopes that will be recognized as foreign and elicit CD8<sup>+</sup> and CD4<sup>+</sup> T cell responses, respectively. The induction of cross-reactive CTLs that recognize

both the heterologous and homologous self-antigen can then lead to lysis of host tumor cells.

Unfortunately, this type of animal model cannot be used to test the efficacy of modified or heterologous tumor antigens being considered for use in humans since mice and humans recognize different epitopes, primarily as a result of differences in their MHC molecules. It may be possible, however, to use the allogeneic human peripheral blood lymphocyte - severe combined immunodeficiency mouse (Hu-PBL-SCID) model. SCID mice lack mature B and T lymphocytes and can be reconstituted with human PBLs. It may be possible to immunize such mice with test antigen to induce a response in adoptively transferred human PBLs and evaluate protection against challenge with a human tumor cell line (Mosier et al., 1988; Parney et al., 1997; Albert et al., 1997).

Another possibility is immunization of HLA-A2.1 transgenic mice to reproduce the immune reactivity of HLA-A2 individuals.

### **Adoptive Immunotherapy and Vaccines**

The expanded populations of antigen-specific immune effector cells of the present invention find use in adoptive immunotherapy regimes and as vaccines.

Adoptive immunotherapy methods involve, in one aspect, administering to a subject a substantially pure population of educated, antigen-specific immune effector cells made by culturing naïve immune effector cells with APCs as described above. Preferably, the APCs are dendritic cells.

In one embodiment, the adoptive immunotherapy methods described herein are autologous. In this case, the APCs are made using parental cells isolated from a single subject. The expanded population also employs T cells isolated from that subject. Finally, the expanded population of antigen-specific cells is administered to the same patient.

In another embodiment, the adoptive immunotherapy methods are allogeneic. Here, cells from two or more patients are used to generate the APCs, and stimulate production of the immune effector cells. For instance, cells from

other healthy or diseased subjects can be used to generate antigen-specific cells in instances where it is not possible to obtain autologous T cells and/or dendritic cells from the subject providing the biopsy. The expanded population can be administered to any one of the subjects from whom cells were isolated, or to  
5 another subject entirely.

In a further embodiment, APCs or immune effector cells are administered with an effective amount of a stimulatory cytokine, such as IL-2 or a co-stimulatory molecule.

The agents identified herein as effective for their intended purpose can be administered to subjects or individuals susceptible to or at risk of developing a  
10 disease, such as cancer. When the agent is administered to a subject such as a mouse, a rat or a human patient, the agent can be added to a pharmaceutically acceptable carrier and systemically or topically administered to the subject. To determine patients that can be beneficially treated, a tumor regression can be  
15 assayed. Therapeutic amounts can be empirically determined and will vary with the pathology being treated, the subject being treated and the efficacy and toxicity of the therapy. When delivered to an animal, the method is useful to further confirm efficacy of the agent. As an example of an animal model, groups of nude mice (Balb/c NCR nu/nu female, Simonsen, Gilroy, CA) are each subcutaneously  
20 inoculated with about  $10^5$  to about  $10^9$  hyperproliferative, cancer or target cells as defined herein. When the tumor is established, the agent is administered, for example, by subcutaneous injection around the tumor. Tumor measurements to determine reduction of tumor size are made in two dimensions using venier calipers twice a week. Other animal models may also be employed as  
25 appropriate.

Administration *in vivo* can be effected in one dose, continuously or intermittently throughout the course of treatment. Methods of determining the most effective means and dosage of administration are well known to those of skill in the art and will vary with the composition used for therapy, the purpose of  
30 the therapy, the target cell being treated, and the subject being treated. Single or



multiple administrations can be carried out with the dose level and pattern being selected by the treating physician. Suitable dosage formulations and methods of administering the agents can be found below.

5 The agents and compositions of the present invention can be used in the manufacture of medicaments and for the treatment of humans and other animals by administration in accordance with conventional procedures, such as an active ingredient in pharmaceutical compositions.

10 More particularly, an agent of the present invention also referred to herein as the active ingredient, may be administered for therapy by any suitable route including nasal, topical (including transdermal, aerosol, buccal and sublingual), parenteral (including subcutaneous, intramuscular, intravenous and intradermal) and pulmonary. It will also be appreciated that the preferred route will vary with the condition and age of the recipient, and the disease being treated.

15 The compositions and methods described herein are particularly useful in providing or inducing a prophylactic immune response in an animal. Animals in a pre-disease state or in a disease free interval, i.e., having or pre-disposed to a condition subject to immune surveillance, are most suitably treated by the methods and compositions described herein. Such conditions involve the activation of an immune response in a diseased state or period.

#### 20 Example

25 Dendritic cells were derived from peripheral blood of a HLA-A2+ human donor using standard GM-CSF/IL-4 culture technique. After six days, the cells were infected with an adenovirus (serotype 2) construct encoding human gp 100. At T=7 days, they were restimulated with  $5 \times 10^5$  infected autologous DCs (from frozen stocks) and given 50 U/ml rhIL-2. At T=14 days, the cultures were treated with leucyl-leucyl-methyl ester in order to eliminate NK cell activity. Immediately after treatment, the cells were washed thoroughly and replated along  
30 with  $1 \times 10^7$  mitomycin C-treated autologous PBMC as feeders. At T=21 days,

cells were split and replated at  $5 \times 10^5$  cells/ml in Iscoves/10% human AB serum/1000U rhIL-2/ml. At T=26 days, the CTLs raised against gp100 were tested in  $^{51}\text{Cr}$ -release assay using peptide pulsed T2 cells as targets. Effector CTLs were TIL 1520 which specifically recognize an HLA-A-A2 restricted epitope of the wild-type human gp100 protein. Figure 5 shows the results of this assay. There is epitope-specific recognition that was not present prior to education of the T cells with the infected DCs.

It is to be understood that while the invention has been described in conjunction with the above embodiments, that the foregoing description and the following examples are intended to illustrate and not limit the scope of the invention. For example, any of the above-noted compositions and/or methods can be combined with known therapies or compositions. Other aspects, advantages and modifications within the scope of the invention will be apparent to those skilled in the art to which the invention pertains.

CLAIMS

1. A method of inducing a prophylactic immune response to a self-antigen in a subject, comprising administering to the subject an effective amount of the antigen or an altered form of the antigen.
2. The method of claim 1, wherein the antigen is administered as a polynucleotide coding for the self-antigen.
3. The method of claim 2, wherein the polynucleotide is delivered as naked DNA.
4. The method of claim 2, wherein the polynucleotide is delivered in a gene delivery vehicle.
5. The method of claim 1, further comprising administering an effective amount of an immunostimulatory agent to the subject.
6. The method of claim 5, wherein the immunostimulatory agent is administered as a polynucleotide coding for the immunostimulatory agent.
7. The method of claim 1, wherein the antigen is administered in an antigen presenting cell.
8. The method of claim 7, wherein the antigen presenting cell has been genetically modified by insertion of a polynucleotide coding for the antigen.
9. The method of claim 7, wherein the antigen presenting cell is a foster antigen presenting cell, a hybrid antigen presenting cell, or a pulsed antigen presenting cell.

10. The method of claim 7, wherein the antigen presenting cell is a dendritic cell.

5 11. The method of claim 7, further comprising administering an effective amount of an immunostimulatory agent to the subject.

12. The method of claim 11, wherein the immunostimulatory agent is administered as a polynucleotide coding for the immunostimulatory agent.

10

13. The method of claim 1 or 7, wherein the self-antigen is a tumor associated antigen (TAA).

14. A method of providing a prophylactic immune response to a self-antigen in a subject, comprising administering to the subject an effective amount of educated immune effector cells, educated to specifically recognize and lyse cells expressing the self-antigen or an altered form of the self-antigen.

15

15. The method of claim 14, wherein the immune effector cells have been produced by stimulating naïve immune effector cells with antigen presenting cells that present the antigen or an altered self-antigen to the naïve immune effector cells.

20

16. The method of claim 14, wherein the educated immune effector cells are produced *ex vivo*.

25

17. The method of claim 14, wherein the educated immune effector cells are produced *in vivo*.

18. The method of claim 14, further comprising administering an effective amount of an immunostimulatory agent.

5 19. The method of claim 18, wherein the immunostimulatory agent is administered as a polynucleotide coding for the immunostimulatory agent.

20. The method of claim 1 or 14, wherein the subject is characterized as being in a disease-free state but genetically predisposed to a condition subject to immune surveillance.

10

21. The method of claim 20, wherein the condition is associated with the presence of the HER-2/neu gene in the subject.

22. The method of claim 1 or 14, wherein the subject is characterized as being in a disease free interval of a condition subject to immune surveillance.

15

23. The method of claim 22, wherein the condition is melanoma.

1/9

FIG. 1A	
FIG. 1B	

FIG. 1

HUMAN	1	MDLVLRCLL	HLAVIGALLA	VGATKVRNQ	DWLGYSRQLR	TKAWNRQLYP	
MOUSE		*G-QR-SF-	PLV-LSA---	---LEGS---	---P---V	--T-----	
	51	EWTEAQRDC	WRGGQVSLKV	SNDGPTLIGA	NASFIALNF	PGSQKVLDPG	
		---V-GSN-	-----R-	----- ---	-----H-	-----	
	101	QVIWYNNTII	NGSQVWGQP	VYPQETDDAC	IFPDGGPCPS	GSWSQKRFSV	
		---A-----	-----P---	-----V	-----	-PKPP-----	
	151	YVWKTWGQYW	QVLGGPYSGL	SIGTGRAMLG	THTMEVTYH	RRGSRSYVPL	
		-----K--	-----R-	--A--H-K--	-----	-----Q-----	
	201	AHSSSAFTIT	DQVPFSVSVS	QLRALDGGNK	HFLRNQPLTF	ALQLHDPSPGY	
		--A--T-----	-----	--Q-----ET-	-----H-- -	-----	
	251	LAEDLSYTW	DFGSSGTLI	SRALVVTHTY	LEPGPVTAQV	VLQAAILPTS	
		-----	---GT---	---D-----	--S-S-----	-----V-	

FIG. 1A

2/9

```

301 CGSSPVPGIT DGHRTAEAP NTTAGQVPTT EVVGTTPGOA PTAEPSGTTT
    -----Y-----G--SR-GT-- -----M--TQ-----V

351 VQVPTTEVIS TAPVOMPTAE STGMTPEKVP VSEVMGTTLA EMSTPEATGM
    -N-----TA -TSE--L--* ***** *A-ID---- -V--T-G--T

401 TPAEVSIVLV SGTTAAQVTT TEWETIARE LPIPEPEGPD ASSIMSTESI
    --T*****P ----V--A-- -----***** ----PLLP-Q-S

451 TGLGLPLLDG TATLRLVKRQ VPLDCVLYRY GSFSVTILDIV QGIESAEILQ
    ---IS----D -D-IM----- ----LA-----

501 AVPSGEGDAF ELTVSCQGLL PKEACMEISS PGCQPPAQLR CQFVLPSAPC
    ---FS----- ----D----- ----S-P---D-

551 QLVLHQILKG GSGTYCLNVS LADINSLAVV STQLIMPQGE AGLGQVPLIV
    -----V----- ----A-----A ----VV---D G---A--L-

601 GILLVLMAVV LASLIYRRRL WKQDFSVPLQ PHSSSHWLRL PRIFCSCPIG
    -----V-----H-H--K--G--S-M --G-T----- -PV-RARGL-

651 ENSPLLSGQQ VX
    -----

```

FIG. 1B





4/9




FIG. 2B

FIG. 3A | FIG. 3B | FIG. 3

1	ACCAGACAGGACTCTCATTAAAGGAAG	TGTCCITGGCCITTGACCCCTACAAGAATGCCA	MetPro
120	ACGGCTGAAGAGGGCGCTGGGATCGGCATC	CIGACAGTGAICCTGIGGAGTCTTACTGCTC	
23	ThraIaGIuGluaIaIaIaGIyIIeGIyIIe	LeuThrValIIleLeuGIyValIleuLeuLeuLeu	
240	CATGITGGCACTCAATIGCGCTTAACAAGA	AGAIGCCACACAAGAAGGGTTTGATCATCGG	
63	HISValGIyThrGInCysAlaLeuThrArg	ArgCysProGIuCInUGIyPheAspHISarg	
360	GCTTATGAGAAACTCTCTGCGAACAAGTCA	CCACCACCTTATTCACCTTAAGAGCCAGCG	
103	AlaTyrgIuLysLeuSerAlaGIuGInSer	ProProProTyrserPro	
480	ATCTAATGTTCTCCTTTGGAATGGTGTAGG	AAAAATGCAAGGCATCTCTATAATAAGTC	
600	TATTAATTTGGGAACACTCCAATAATAAT	GTTCRAATGCATACATACTCTGTGCCAGA	
720	GSGGCCATCCAAATTCCTCTTACTTCAAAT	TTGGCTAAATAACAACACTAGTCAGGTTTTCG	
840	GATACCTTACAGGTTAAGACAAGGGTTG	ACTGGCTATTATTCTGATCAAGAACATGT	
960	CTTAGCTCTTTTTTTTGAGATGGASIT	CGCTTTGTIGCCCAGGCTGGAGTGCCAATG	
1080	CTCCTGAGTAGCTGGGATTACAGGGGTGC	GCCACTATGCCCTGACTAATTTGTAGTTTT	
1200	TGTGCCGCTCACGCTCCCAAAGTGTCTG	AATTACAGGGTGTAGCCACCACCGCTGGCT	
1320	AATGCTATTCTAACTAATGACAAGTATTT	CTACTAAACCCAGAAATTTGGTAGAAGGATTT	
1440	TACCTATGSCAAATTAGCTCTCTTGGGTTTC	CCAAATCCCTCTCACAAGAAATGTCCAGAAG	

## FIG. 3A

6/9

AGAGAAGATGCTCACTTCTATCTATGGTTAC	CCCAAGAAGGGGACAGGCCACTCTTTACACC	119
ArgGluAspAlaHisPheIleTyrGlyTyr	ProLysLysGlyHisGlyHisSerTyrThr	22
ATCGGCTGTGGTATTGTAGAAGACGAAAT	GGATACAGAGCCTTGCATGGATAAAAGTCTT	239
IleGlyCysIrpIyrCysArgArgArgasn	GlyTyrArgAlaLeuMetAspLysSerLeu	62
GACAGCAAAGTGTCTCTTCAAGAGAAAAAC	TGTGAACCTGTGGTTCCTCAATGCTCCACCT	359
AspSerLysValSerLeuGlnGlnLysasn	CysGluProValValProAsnAlaProPro	102
AGACACCTGAGACATGCTGAAATTATTTCT	CTCACACTTTTGCTTGAATTTAATACAGAC	479
		118
AGGTIAAAATTTTAGTAGTCCGCTAGCA	GTACTAATCAITGTCAGGAAATGATGAGAA	599
GGTAATGTTAGTAAATCCATGGGTATTAT	TCTGAGAGACAGAAATCAAGTGGGTATTCT	719
AACCTTGACCGACATGACGTACACAGAA	TTGTTCCAGTACTATGGAGTGCCTCACAAG	839
CAGCAATGCTCTTTGGCTCTAAATTTCT	ATTATACTACAATAATATATTGTAAAGATC	959
GCAGGATCTTGGCTCACCATAACCTCCGCC	TCCCAGGTTCAACCAATTTCTCCTGCCCTTAG	1079
AGTAGACACGGGGTTTCATCATGTTGGTCA	GGCTGGTCTCAACACTCCTGACCICAGGTGA	1199
GGATCCATATATCTTAGGTAAACATATAAC	GCAGTCTAATTAACATTTCACTTCAAGGCTC	1319
AAATAAGTAAAGCTACTATGTACTGCCCTT	AGTGCATGCGCTGTGTACTGCCCTTAAATG	1439
AAATCATAAAGGATCAGAGATCTTGAAAA	AAAAAAAAAAAAAAAAAAAAAAAAAAAAA	1559

FIG. 3B

7/9

FIG. 4	
FIG. 4A	FIG. 4B

MOUSE TRP2

1 MGLVGWGLLL GCLGGILLR ARAQFRVCM TLDGVLNKEC CPPLGPEATN  
 51 ICGFLEGRGQ CAEQIDTRP WSGPYILRNQ DDREQWPRKF FNRICKCTGN  
 101 FAGYNCGGCK FGWTGPDENR KKPAILRRNI HSLIAQEREQ FLGALDLAKK  
 151 SIHPDYVITT QHWLGLLGN GTQPIANC VYDFFVWLHY YSVRDILLGP  
 201 GRPYKAIDFS HQGPAFVTHW RYHLLWLERE LQRLTGNESF ALPYWNFATG  
 251 KNECDVCTDD WLGAARQDDP TLI SRNSRFS TWEIYCDSD DYNRRVTLCN  
 301 GTYEGLLRRN KVGRRNEKLP TLKNVQDCLS LQKFDSPFF QNSTFSFNA  
 351 LEGFDKADGT LDSQVMNLHN LAHSFLNGIN ALPHSAANDP VFVVLHSFTD  
 401 AIFDEWLKRN NPSTDAWPQE LAPIGHNRMV NMVPFFPPVT NEELFLTAEQ  
 451 LGYNYAVDLS EEEAPVWSTT LGVVIGILGA FVLLGLLAF LQYRRLKGY  
 501 APLMETGLSS KRYTEEA

FIG. 4A

8/9

## HUMAN TRP2

1 MSPLWWGELL SCLOCKILPG AQQFPRVCM TVDSLYNKEC CPRLGAESAN  
 51 VCGSQQGRGQ CIEVRADIRP WSGPYILRNQ DDRELWPRKF FHRTCKCTGN  
 101 FAGYNCGDCK FGWTGPNCER KKPPVIRQNI HSLSPQEREQ FLGALDLAKK  
 151 RVHPDYVITT QHWLGLLGPN GTQPQFANCS VYDFFVWLHY YSVRDILLGP  
 201 GRPYRAIDFS HQGPAFVTWH RYHLLCLERD LQRLIGNESF ALPYWNFATG  
 251 RNECDVCTDQ LFGAARPDOP TLISRSRFS SWETVCDSDLD DYNHLVTLGN  
 301 GTYEGLLLRN QMGRNSMKLP TLKDIRDCLS LQKFDNPPFF QNSTFSFRNA  
 351 LEGFDKADGT LDSQVMSLHN LVHSFLNGTN ALPHSAANDP IFVVLHSFTD  
 401 AIFDEWMKRF NPPADAWPQE LAPIGHNRMV NMVPFFPPVT NEELFLTSDQ  
 451 LGYSYAIIDL PVSVEETPGWP TTLLVVMGTL VALVGLFVLL AFLQYRRLRK  
 501 GYTPLMETHL SSKRYTEEA

FIG. 4B

9/9




FIG. 5

## SEQUENCE LISTING

<110> Nicolette, Charles A.  
Genzyme Corporation

<120> COMPOSITIONS AND METHODS FOR ANTIGEN-SPECIFIC  
VACCINATION

<130> 159792001040

<140> Unassigned

<141> 1999-03-19

<150> 60/078,890

<151> 1998-03-20

<160> 17

<170> Patentin Ver. 2.0

<210> 1

<211> 662

<212> PRT

<213> Homo sapiens

<400> 1

Met Asp Leu Val Leu Lys Arg Cys Leu Leu His Leu Ala Val Ile Gly  
1 5 10 15

Ala Leu Leu Ala Val Gly Ala Thr Lys Val Pro Arg Asn Gln Asp Trp  
20 25 30

Leu Gly Val Ser Arg Gln Leu Arg Thr Lys Ala Trp Asn Arg Gln Leu  
35 40 45

Tyr Pro Glu Trp Thr Glu Ala Gln Arg Leu Asp Cys Trp Arg Gly Gly  
50 55 60

Gln Val Ser Leu Lys Val Ser Asn Asp Gly Pro Thr Leu Ile Gly Ala  
65 70 75 80

Asn Ala Ser Phe Ser Ile Ala Leu Asn Phe Pro Gly Ser Gln Lys Val  
85 90 95

Leu Pro Asp Gly Gln Val Ile Trp Val Asn Asn Thr Ile Ile Asn Gly  
100 105 110

Ser Gln Val Trp Gly Gly Gln Pro Val Tyr Pro Gln Glu Thr Asp Asp  
115 120 125

Ala Cys Ile Phe Pro Asp Gly Gly Pro Cys Pro Ser Gly Ser Trp Ser  
130 135 140

Gln Lys Arg Ser Phe Val Tyr Val Trp Lys Thr Trp Gly Gln Tyr Trp  
145 150 155 160

Gln Val Leu Gly Gly Pro Val Ser Gly Leu Ser Ile Gly Thr Gly Arg  
165 170 175

Ala Met Leu Gly Thr His Thr Met Glu Val Thr Val Tyr His Arg Arg  
180 185 190

Gly Ser Arg Ser Tyr Val Pro Leu Ala His Ser Ser Ser Ala Phe Thr  
 195 200 205  
 Ile Thr Asp Gln Val Pro Phe Ser Val Ser Val Ser Gln Leu Arg Ala  
 210 215 220  
 Leu Asp Gly Gly Asn Lys His Phe Leu Arg Asn Gln Pro Leu Thr Phe  
 225 230 235 240  
 Ala Leu Gln Leu His Asp Pro Ser Gly Tyr Leu Ala Glu Ala Asp Leu  
 245 250 255  
 Ser Tyr Thr Trp Asp Phe Gly Asp Ser Ser Gly Thr Leu Ile Ser Arg  
 260 265 270  
 Ala Leu Val Val Thr His Thr Tyr Leu Glu Pro Gly Pro Val Thr Ala  
 275 280 285  
 Gln Val Val Leu Gln Ala Ala Ile Pro Leu Thr Ser Cys Gly Ser Ser  
 290 295 300  
 Pro Val Pro Gly Thr Thr Asp Gly His Arg Pro Thr Ala Glu Ala Pro  
 305 310 315 320  
 Asn Thr Thr Ala Gly Gln Val Pro Thr Thr Glu Val Val Gly Thr Thr  
 325 330 335  
 Pro Gly Gln Ala Pro Thr Ala Glu Pro Ser Gly Thr Thr Ser Val Gln  
 340 345 350  
 Val Pro Thr Thr Glu Val Ile Ser Thr Ala Pro Val Gln Met Pro Thr  
 355 360 365  
 Ala Glu Ser Thr Gly Met Thr Pro Glu Lys Val Pro Val Ser Glu Val  
 370 375 380  
 Met Gly Thr Thr Leu Ala Glu Met Ser Thr Pro Glu Ala Thr Gly Met  
 385 390 395 400  
 Thr Pro Ala Glu Val Ser Ile Val Val Leu Ser Gly Thr Thr Ala Ala  
 405 410 415  
 Gln Val Thr Thr Thr Glu Trp Val Glu Thr Thr Ala Arg Glu Leu Pro  
 420 425 430  
 Ile Pro Glu Pro Glu Gly Pro Asp Ala Ser Ser Ile Met Ser Thr Glu  
 435 440 445  
 Ser Ile Thr Gly Ser Leu Gly Pro Leu Leu Asp Gly Thr Ala Thr Leu  
 450 455 460  
 Arg Leu Val Lys Arg Gln Val Pro Leu Asp Cys Val Leu Tyr Arg Tyr  
 465 470 475 480  
 Gly Ser Phe Ser Val Thr Leu Asp Ile Val Gln Gly Ile Glu Ser Ala  
 485 490 495  
 Glu Ile Leu Gln Ala Val Pro Ser Gly Glu Gly Asp Ala Phe Glu Leu  
 500 505 510



Thr Val Ser Cys Gln Gly Gly Leu Pro Lys Glu Ala Cys Met Glu Ile  
 515 520 525  
 Ser Ser Pro Gly Cys Gln Pro Pro Ala Gln Arg Leu Cys Gln Pro Val  
 530 535 540  
 Leu Pro Ser Pro Ala Cys Gln Leu Val Leu His Gln Ile Leu Lys Gly  
 545 550 555 560  
 Gly Ser Gly Thr Tyr Cys Leu Asn Val Ser Leu Ala Asp Thr Asn Ser  
 565 570 575  
 Leu Ala Val Val Ser Thr Gln Leu Ile Met Pro Gly Gln Glu Ala Gly  
 580 585 590  
 Leu Gly Gln Val Pro Leu Ile Val Gly Ile Leu Leu Val Leu Met Ala  
 595 600 605  
 Val Val Leu Ala Ser Leu Ile Tyr Arg Arg Arg Leu Met Lys Gln Asp  
 610 615 620  
 Phe Ser Val Pro Gln Leu Pro His Ser Ser Ser His Trp Leu Arg Leu  
 625 630 635 640  
 Pro Arg Ile Phe Cys Ser Cys Pro Ile Gly Glu Asn Ser Pro Leu Leu  
 645 650 655  
 Ser Gly Gln Gln Val Xaa  
 660

<210> 2  
 <211> 4  
 <212> PRT  
 <213> Mus musculus

<400> 2  
 Leu Glu Gly Ser  
 1

<210> 3  
 <211> 4  
 <212> PRT  
 <213> Mus musculus

<400> 3  
 Pro Lys Pro Pro  
 1

<210> 4  
 <211> 4  
 <212> PRT  
 <213> Mus musculus

<400> 4  
 Pro Leu Leu Pro  
 1

<210> 5  
 <211> 5  
 <212> PRT  
 <213> Mus musculus

<400> 5  
 Arg Ala Arg Gly Leu  
 1 5

<210> 6  
 <211> 23  
 <212> DNA  
 <213> Mus musculus

<400> 6  
 atgccccaa g aagacattca ctt 23

<210> 7  
 <211> 295  
 <212> DNA  
 <213> Mus musculus

<400> 7  
 tgggttatccc aggaaggggg acagacgctc ctatgtcact gctgaagagg ccgcagggat 60  
 cggcatcctcg atcgtgggtc tggggattgc tctgcttate ggctgctggt actgtagaag 120  
 acgaagtggg tacagaacct tgatggacaa aaggcgtcat attggtatc aaaaaacctc 180  
 aagggaaga tgctcatgtg agagccctga tcaccaggac agccgactgt cttctcaaga 240  
 gaaatcccat cagccctggt tcccaacgc tccgctgctc tatgagaagc tctct 295

<210> 8  
 <211> 24  
 <212> DNA  
 <213> Mus musculus

<400> 8  
 tcaccgccac ctattccac ctga 24

<210> 9  
 <211> 357  
 <212> DNA  
 <213> Homo sapiens

<400> 9  
 atgccaaag aagatgctca ctctatctat gggtacccca agaaggggca cggccactct 60  
 tacaccacgg ctgaagaggc cgtctgggac ggcactctga cagtgatcct gggagtctta 120  
 ctgctcatcg gctgttggta ttgtagaaga cgaatggat acagagcctt gatggataaa 180  
 agtcttcctg ttggcactca atgtgcctta acaagaagat gccacacaaga aggggtttgat 240  
 cctcgggaca gcaaatgtc tcttcaagag aaaaactgtg aacctgtggt tcccaatgct 300

ccaccgagcct atgagaaact ctctgcagaa cagtcaccac caccctatcc accttaa 357

<210> 10  
 <211> 8  
 <212> PRT  
 <213> Mus musculus

<400> 10  
 Met Pro Gln Glu Asp Ile His Phe  
 1 5

<210> 11  
 <211> 98  
 <212> PRT  
 <213> Mus musculus

<400> 11  
 Gly Tyr Pro Arg Lys Gly His Arg Arg Ser Tyr Val Thr Ala Glu Glu  
 1 5 10 15  
 Ala Ala Gly Ile Gly Ile Leu Ile Val Val Leu Gly Ile Ala Leu Leu  
 20 25 30  
 Ile Gly Cys Trp Tyr Cys Arg Arg Arg Ser Gly Tyr Arg Thr Leu Met  
 35 40 45  
 Asp Lys Arg Arg His Ile Gly Ile Gln Lys Thr Ser Arg Glu Arg Cys  
 50 55 60  
 Ser Cys Glu Ser Pro Asp His Gln Asp Ser Arg Leu Ser Ser Gln Glu  
 65 70 75 80  
 Lys Ser His Gln Pro Val Val Pro Asn Ala Pro Pro Ala Tyr Glu Lys  
 85 90 95  
 Leu Ser

<210> 12  
 <211> 8  
 <212> PRT  
 <213> Mus musculus

<400> 12  
 Ser Pro Pro Pro Tyr Ser Pro Xaa  
 1 5

<210> 13  
 <211> 119  
 <212> PRT  
 <213> Homo sapiens

<400> 13  
 Met Pro Arg Glu Asp Ala His Phe Ile Tyr Gly Tyr Pro Lys Lys Gly  
 1 5 10 15  
 His Gly His Ser Tyr Thr Thr Ala Glu Glu Ala Ala Gly Ile Gly Ile

20	25	30	
Leu Thr Val Ile Leu Gly Val Leu Leu Leu Ile Gly Cys Trp Tyr Cys			
35	40	45	
Arg Arg Arg Asn Gly Tyr Arg Ala Leu Met Asp Lys Ser Leu His Val			
50	55	60	
Gly Thr Gln Cys Ala Leu Thr Arg Arg Cys Pro Gln Glu Gly Phe Asp			
65	70	75	80
His Arg Asp Ser Lys Val Ser Leu Gln Glu Lys Asn Cys Glu Pro Val			
85	90	95	
Val Pro Asn Ala Pro Pro Ala Tyr Glu Lys Leu Ser Ala Glu Gln Ser			
100	105	110	
Pro Pro Pro Tyr Ser Pro Xaa			
115			
<210> 14			
<211> 1559			
<212> DNA			
<213> Homo sapiens			
<220>			
<221> CDS			
<222> (54)..(407)			
<400> 14			
agcagacaga ggacgtctcat taaggaaggt gtcctgtgcc ctgacctac aag atg		56	
	Met		
	1		
cca aga gaa gat gct cac ttc atc tat ggt tac ccc aag aag ggg cac		104	
Pro Arg Glu Asp Ala His Phe Ile Tyr Gly Tyr Pro Lys Lys Gly His			
5	10	15	
ggc cac tct tac acc acg gct gaa gag gcc gct ggg atc ggc atc ctg		152	
Gly His Ser Tyr Thr Thr Ala Glu Glu Ala Ala Gly Ile Gly Ile Leu			
20	25	30	
aca gtg atc ctg gga gtc tta ctg ctc atc ggc tgt tgg tat tgt aga		200	
Thr Val Ile Leu Gly Val Leu Leu Leu Ile Gly Cys Trp Tyr Cys Arg			
35	40	45	
aga cga aat gga tac aga gcc ttg atg gat aaa agt ctt cat gtt ggc		248	
Arg Arg Asn Gly Tyr Arg Ala Leu Met Asp Lys Ser Leu His Val Gly			
50	55	60	65
act caa tgt gcc tta aca aga aga tgc cca caa gaa ggg ttt gat cat		296	
Thr Gln Cys Ala Leu Thr Arg Arg Cys Pro Gln Glu Gly Phe Asp His			
70	75	80	
cgg gac agc aaa gtg tct ctt caa gag aaa aac tgt gaa cct gtg gtt		344	
Arg Asp Ser Lys Val Ser Leu Gln Glu Lys Asn Cys Glu Pro Val Val			
85	90	95	
ccc aat gct cca cct gct tat gag aaa ctc tct gca gaa cag tca cca		392	
Pro Asn Ala Pro Pro Ala Tyr Glu Lys Leu Ser Ala Glu Gln Ser Pro			

```

100      105      110
cca cct tat tca cct taagagccag cgagacacct gagacatgct gaaattattt 447
Pro Pro Tyr Ser Pro
115
ctctccacct ttgtcttgaa ttttaatacag acatctaatg ttctcctttg gaatgggtga 507
ggaaaaaatgc aagccatctc taataataag tcagtgttaa aatttttagta ggcccgctag 567
cagtactaat catgtgagga aatgatgaga aatattaaat cgggaaaaat ccatcaataa 627
atgttgcaat gcatgatact atctgtgccg gaggtaatgt tagtaaatcc atggtgttat 687
ttctcgagag acagaattca agtgggtatt cgggggccat ccaatttctc ttactctgaa 747
atttggctaa taacaaacta gtcagggttt cgaacctga ccgacatgaa ctgtacacag 807
aattgttcca gtactatgga gtgctcaca aggatacttt tacaggttaa gacaaagggc 867
tgactggcct atttatctga tcaagaacat gtcagcaatg tctctttgtg ctctaaaaat 927
ctattatact acaataatat attgtaasga tcttatagct cttttttttt gagatggagt 987
tgcctttttg ttgccagagc tggagtgcaa tggcgcgatc ttggctcacc ataacctccg 1047
cctccaggtt tcaagcaatt ctctgcctt agcctcctga gtagctggga ttacaggcgt 1107
gggccactat gctgactaa ttttgtagtt ttagtagaga cgggggtttc ccatgttggc 1167
caggctggtc tcaaaactct gacctcaggt gatctgcctg cctcagcttc ccaaaagtgc 1227
ggaattacag gctgagoca ccacgctgg ctggatctta tctcttaagt aagacatata 1287
aocgagtcct attacatttc acttcaagga tcaatgctat tctaaactaa gacaagtatt 1347
ttctactaaa ccagaaattg gtagaaggat ttaataaagt aaaagctact atgtaactgc 1407
ttagtgctga tgcctgtgta ctgccttaaa tgtacctatg gcaatttagc tctcttgggt 1467
tcccaaatcc ctctcacaag aatgtgcaga agaaatcata aaggatcaga gattctgaaa 1527
aaaaaaaaa aaaaaaaaaa aaaaaaaaaa aa 1559

```

&lt;210&gt; 15

&lt;211&gt; 118

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 15

```

Met Pro Arg Glu Asp Ala His Phe Ile Tyr Gly Tyr Pro Lys Lys Gly
 1           5           10          15

```

```

His Gly His Ser Tyr Thr Thr Ala Glu Glu Ala Ala Gly Ile Gly Ile
 20           25           30

```

```

Leu Thr Val Ile Leu Gly Val Leu Leu Ile Gly Cys Trp Tyr Cys
 35           40           45

```

```

Arg Arg Arg Asn Gly Tyr Arg Ala Leu Met Asp Lys Ser Leu His Val

```

50                      55                      60  
 Gly Thr Gln Cys Ala Leu Thr Arg Arg Cys Pro Gln Glu Gly Phe Asp  
 65                      70                      75                      80  
 His Arg Asp Ser Lys Val Ser Leu Gln Glu Lys Asn Cys Glu Pro Val  
 85                      90                      95  
 Val Pro Asn Ala Pro Pro Ala Tyr Glu Lys Leu Ser Ala Glu Gln Ser  
 100                      105                      110  
 Pro Pro Pro Tyr Ser Pro  
 115  
  
 <210> 16  
 <211> 517  
 <212> PRT  
 <213> Mus Musculus  
  
 <400> 16  
 Met Gly Leu Val Gly Trp Gly Leu Leu Leu Gly Cys Leu Gly Cys Gly  
 1                      5                      10                      15  
 Ile Leu Leu Arg Ala Arg Ala Gln Phe Pro Arg Val Cys Met Thr Leu  
 20                      25                      30  
 Asp Gly Val Leu Asn Lys Glu Cys Cys Pro Pro Leu Gly Pro Glu Ala  
 35                      40                      45  
 Thr Asn Ile Cys Gly Phe Leu Glu Gly Arg Gly Gln Cys Ala Glu Val  
 50                      55                      60  
 Gln Thr Asp Thr Arg Pro Trp Ser Gly Pro Tyr Ile Leu Arg Asn Gln  
 65                      70                      75                      80  
 Asp Asp Arg Glu Gln Trp Pro Arg Lys Phe Phe Asn Arg Thr Cys Lys  
 85                      90                      95  
 Cys Thr Gly Asn Phe Ala Gly Tyr Asn Cys Gly Gly Cys Lys Phe Gly  
 100                      105                      110  
 Trp Thr Gly Pro Asp Cys Asn Arg Lys Lys Pro Ala Ile Leu Arg Arg  
 115                      120                      125  
 Asn Ile His Ser Leu Thr Ala Gln Glu Arg Glu Gln Phe Leu Gly Ala  
 130                      135                      140  
 Leu Asp Leu Ala Lys Lys Ser Ile His Pro Asp Tyr Val Ile Thr Thr  
 145                      150                      155                      160  
 Gln His Trp Leu Gly Leu Leu Gly Pro Asn Gly Thr Gln Pro Gln Ile  
 165                      170                      175  
 Ala Asn Cys Ser Val Tyr Asp Phe Phe Val Trp Leu His Tyr Tyr Ser  
 180                      185                      190  
 Val Arg Asp Thr Leu Leu Gly Pro Gly Arg Pro Tyr Lys Ala Ile Asp  
 195                      200                      205  
 Phe Ser His Gln Gly Pro Ala Phe Val Thr Trp His Arg Tyr His Leu

210	215	220
Leu Trp Leu Glu Arg	Glu Leu Gln Arg	Leu Thr Gly Asn Glu Ser Phe
225	230	235
Ala Leu Pro Tyr Trp	Asn Phe Ala Thr Gly	Lys Asn Glu Cys Asp Val
	245	250
Cys Thr Asp Asp	Trp Leu Gly Ala Ala	Arg Gln Asp Asp Pro Thr Leu
	260	265
Ile Ser Arg Asn Ser	Arg Phe Ser Thr Trp	Glu Ile Val Cys Asp Ser
	275	280
Leu Asp Asp Tyr	Asn Arg Arg Val Thr	Leu Cys Asn Gly Thr Tyr Glu
	290	295
Gly Leu Leu Arg	Arg Asn Lys Val Gly	Arg Asn Asn Glu Lys Leu Pro
	305	310
Thr Leu Lys Asn	Val Gln Asp Cys Leu	Ser Leu Gln Lys Phe Asp Ser
	325	330
Pro Pro Phe Phe	Gln Asn Ser Thr Phe	Ser Phe Arg Asn Ala Leu Glu
	340	345
Gly Phe Asp Lys	Ala Asp Gly Thr Leu	Asp Ser Gln Val Met Asn Leu
	355	360
His Asn Leu Ala	His Ser Phe Leu	Asn Gly Thr Asn Ala Leu Pro His
	370	375
Ser Ala Ala Asn	Asp Pro Val Phe Val	Val Leu His Ser Phe Thr Asp
	385	390
Ala Ile Phe Asp	Glu Trp Leu Lys Arg	Asn Asn Pro Ser Thr Asp Ala
	405	410
Trp Pro Gln Glu	Leu Ala Pro Ile Gly	His Asn Arg Met Tyr Asn Met
	420	425
Val Pro Phe Phe	Pro Pro Val Thr	Asn Glu Glu Leu Phe Leu Thr Ala
	435	440
Glu Gln Leu Gly	Tyr Asn Tyr Ala Val	Asp Leu Ser Glu Glu Glu Ala
	450	455
Pro Val Trp Ser	Thr Thr Leu Ser Val	Val Ile Gly Ile Leu Gly Ala
	465	470
Phe Val Leu Leu	Gly Leu Leu Ala Phe	Leu Gln Tyr Arg Arg Leu
	485	490
Arg Lys Gly Tyr	Ala Pro Leu Met Glu	Thr Gly Leu Ser Ser Lys Arg
	500	505
Tyr Thr Glu Glu	Ala	
	515	

&lt;210&gt; 17

&lt;211&gt; 519

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 17

Met Ser Pro Leu Trp Trp Gly Phe Leu Leu Ser Cys Leu Gly Cys Lys  
 1 5 10 15

Ile Leu Pro Gly Ala Gln Gly Gln Phe Pro Arg Val Cys Met Thr Val  
 20 25 30

Asp Ser Leu Val Asn Lys Glu Cys Cys Pro Arg Leu Gly Ala Glu Ser  
 35 40 45

Ala Asn Val Cys Gly Ser Gln Gln Gly Arg Gly Gln Cys Thr Glu Val  
 50 55 60

Arg Ala Asp Thr Arg Pro Trp Ser Gly Pro Tyr Ile Leu Arg Asn Gln  
 65 70 75 80

Asp Asp Arg Glu Leu Trp Pro Arg Lys Phe Phe His Arg Thr Cys Lys  
 85 90 95

Cys Thr Gly Asn Phe Ala Gly Tyr Asn Cys Gly Asp Cys Lys Phe Gly  
 100 105 110

Trp Thr Gly Pro Asn Cys Glu Arg Lys Lys Pro Pro Val Ile Arg Gln  
 115 120 125

Asn Ile His Ser Leu Ser Pro Gln Glu Arg Glu Gln Phe Leu Gly Ala  
 130 135 140

Leu Asp Leu Ala Lys Lys Arg Val His Pro Asp Tyr Val Ile Thr Thr  
 145 150 155 160

Gln His Trp Leu Gly Leu Leu Gly Pro Asn Gly Thr Gln Pro Gln Phe  
 165 170 175

Ala Asn Cys Ser Val Tyr Asp Phe Phe Val Trp Leu His Tyr Tyr Ser  
 180 185 190

Val Arg Asp Thr Leu Leu Gly Pro Gly Arg Pro Tyr Arg Ala Ile Asp  
 195 200 205

Phe Ser His Gln Gly Pro Ala Phe Val Thr Trp His Arg Tyr His Leu  
 210 215 220

Leu Cys Leu Glu Arg Asp Leu Gln Arg Leu Ile Gly Asn Glu Ser Phe  
 225 230 235 240

Ala Leu Pro Tyr Trp Asn Phe Ala Thr Gly Arg Asn Glu Cys Asp Val  
 245 250 255

Cys Thr Asp Gln Leu Phe Gly Ala Ala Arg Pro Asp Asp Pro Thr Leu  
 260 265 270

Ile Ser Arg Asn Ser Arg Phe Ser Ser Trp Glu Thr Val Cys Asp Ser  
 275 280 285

Leu Asp Asp Tyr Asn His Leu Val Thr Leu Cys Asn Gly Thr Tyr Glu  
 290 295 300



Gly Leu Leu Arg Arg Asn Gln Met Gly Arg Asn Ser Met Lys Leu Pro  
 305 310 315 320  
 Thr Leu Lys Asp Ile Arg Asp Cys Leu Ser Leu Gln Lys Phe Asp Asn  
 325 330 335  
 Pro Pro Phe Phe Gln Asn Ser Thr Phe Ser Phe Arg Asn Ala Leu Glu  
 340 345 350  
 Gly Phe Asp Lys Ala Asp Gly Thr Leu Asp Ser Gln Val Met Ser Leu  
 355 360 365  
 His Asn Leu Val His Ser Phe Leu Asn Gly Thr Asn Ala Leu Pro His  
 370 375 380  
 Ser Ala Ala Asn Asp Pro Ile Phe Val Val Leu His Ser Phe Thr Asp  
 385 390 395 400  
 Ala Ile Phe Asp Glu Trp Met Lys Arg Phe Asn Pro Pro Ala Asp Ala  
 405 410 415  
 Trp Pro Gln Glu Leu Ala Pro Ile Gly His Asn Arg Met Tyr Asn Met  
 420 425 430  
 Val Pro Phe Phe Pro Pro Val Thr Asn Glu Glu Leu Phe Leu Thr Ser  
 435 440 445  
 Asp Gln Leu Gly Tyr Ser Tyr Ala Ile Asp Leu Pro Val Ser Val Glu  
 450 455 460  
 Glu Thr Pro Gly Trp Pro Thr Thr Leu Leu Val Val Met Gly Thr Leu  
 465 470 475 480  
 Val Ala Leu Val Gly Leu Phe Val Leu Leu Ala Phe Leu Gln Tyr Arg  
 485 490 495  
 Arg Leu Arg Lys Gly Tyr Thr Pro Leu Met Glu Thr His Leu Ser Ser  
 500 505 510  
 Lys Arg Tyr Thr Glu Glu Ala  
 515

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/06034

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC(6) : Please See Extra Sheet. US CL : Please See Extra Sheet. According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) U.S. : 424/184.1, 277.1, 287.1, 93.2, 93.71, 435/372, 373, 514/2, 44, 530/350, 806, 827, 828, 536/23.1, 23.5 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) DIALOG medicine index, APS, WEST		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A, P	LIU, M. Transfected human dendritic cells as cancer vaccines. Nat. Biotech. April 1988, Vol. 16, pages 335-336, see entire document.	1-23
A	DONNELLY, J.J. et al. DNA vaccines. Ann. Rev. Immunol. 1997, Vol. 15, pages 617-648, see entire document.	1-23
A, P	PARDOLL, D.M. Cancer vaccines. Nature Medicine. May 1998, Vol. 4, No.5(suppl.), pages 525-531, see entire document.	1-23
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: *A* document defining the general state of the art which is not considered to be of particular relevance *E* earliest document published on or after the international filing date *L* document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another reference or other special reason (as specified) *O* document referring to no oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed ** later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone **X* document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art *A* document member of the same patent family		
Date of the actual completion of the international search 29 JUNE 1999		Date of mailing of the international search report 03 AUG 1999
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer F PIERRE VANDERVEGT Telephone No. (703) 308-0196

## INTERNATIONAL SEARCH REPORT

 International application No.  
 PCT/US99/06034

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	BOCZKOWSKI, D. et al. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J. Exp. Med. 01 August 1996, Vol. 184, No. 2, pages 465-472, see entire document, abstract in particular.	1-3, 7-10, 14-17, 20, 22
X	US 5,679,647 A (CARSON et al) 21 October 1997, see entire document.	1-3, 13, 20-23
X, P ---- Y, P	US 5,844,075 A (KAWAKAMI et al) 01 December 1998, see entire document.	1, 13, 20, 22-23 ---- 2-12, 14-19, 21

INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/06034

A. CLASSIFICATION OF SUBJECT MATTER:  
IPC (6):

A01N 37/18, 43/04, 63/00; A61K 31/70, 35/12, 35/36, 39/00; C12N 5/02, 5/06; C07K 1/00; C07H 21/02, 21/04

A. CLASSIFICATION OF SUBJECT MATTER:  
US CL :

424/184.1, 277.1, 287.1, 93.2, 93.71; 435/372, 373; 514/2, 44; 530/350, 806, 827, 828; 536/23.1, 23.5